Dateline City:
KENILWORTH, N.J.
Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new research investigating the use of KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in multiple tumor
types, both as a single agent and in combination with other therapies,
will be presented at this years American Association for Cancer
Research (AACR) Annual Meeting in New Orleans, April 16 20.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more